Diabetes affects millions worldwide, often triggering complications such as insulin resistance and fatty liver disease. To ...

The rise of GLP-1s, which were initially approved for diabetes management and later for obesity treatment, underscores this ...

TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up ...

This simple, cost-effective tool has the potential to revolutionize type 2 diabetes care, helping millions of people ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Broad access to new obesity drugs leads to longer, healthier lives, delivering a substantial societal return on investment, ...

Biomedical engineer Joshua Doloff uses federal funding to pioneer immunotherapies that could free diabetes patients from ...

In patients with diabetes, semaglutide use was associated with an increased risk for nonarteritic anterior ischemic optic ...

ATTD conference, experts debated whether patients who use continuous glucose monitoring should aim for normal glycemia.

The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...